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Clinical studies have shown the similarity of the spectrum of physiological effects of
Selank and classical benzodiazepines, such as diazepam and phenazepam. These
data suggest that there is a similar basis of their mechanism of action. To test this
hypothesis we studied the effect of Selank and GABA on the expression of genes
involved in neurotransmission. We analyzed the expression of 84 genes involved in
neurotransmission (e.g., major subunit of the GABA receptor, transporters, ion channels,
dopamine, and serotonin receptors) in the frontal cortex of rats 1 and 3 h after the
administration of Selank or GABA (300µg/kg) using real-time PCR method. We found
significant changes in the expression of 45 genes 1 h after the administration of the
compounds. Three hours after Selank or GABA administration, 22 genes changed their
expression. We found positive correlation between the changes in genes expression
within 1 h after administration of Selank or GABA. Our results showed that Selank caused
a number of alterations in the expression of genes involved in neurotransmission. The
data obtained indicate that Selank is characterized by its complex effects on nerve cells,
and one of its possible molecular mechanisms is associated with allosteric modulation
of the GABAergic system.
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INTRODUCTION
Regulatory peptides play key roles in the formation, development, and normal functioning of the
nervous system. They are not understood fully despite the accumulating experimental data in
recent years. The study of their mechanisms of action is of particular interest because regulatory
peptides have potential in the creation of safe drugs on their basis with specific clinical properties
and direct physiological effects. One representative of this class of drugs is the synthetic regulatory
peptide Selank. It was designed and produced at the Institute of Molecular Genetics, Russian
Academy of Sciences, in cooperation with the V.V. Zakusov Research Institute of Pharmacology,
Russian Academy of Medical Sciences. Selank is a synthetic analog of the endogenous tuftsin
molecule (the short Thr-Lys-Pro-Arg fragment of the human immunoglobulin G heavy chain),
which was elongated at the C terminus via the addition of three natural L-amino acids (Pro-Gly-
Pro) to improve its metabolic stability and yield a relatively longer duration (Ashmarin et al., 2005;
Ashmarin, 2007).
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Selank has pronounced anxiolytic activity and acts as a
stable neuropsychotropic, antidepressant, and antistress drug
that relieves aggression and fear reaction in different animal
species (Kozlovskii and Danchev, 2002; Sollertinskaya et al.,
2008; Semenova et al., 2010). Selank also has a nootropic
action, which positively influences the formation of memory
and learning processes (Kost et al., 2001; Sokolov et al., 2002;
Semenova et al., 2007, 2009; Narkevich et al., 2008), and marked
immunomodulatory activity (Uchakina et al., 2008; Ershov et al.,
2009; Andreeva et al., 2010).
Clinical studies have shown that the effect of Selank is similar
to that of tranquilizers at low doses, but is not accompanied
by the unwanted side effects of benzodiazepine tranquilizers
such as amnesia, withdrawal, and dependence (Seredenin et al.,
1990, 1998). Benzodiazepines are allosteric modulators of
the type-A γ-aminobutyric acid receptor (GABAAR) and can
increase the inhibitory action of GABA, the major inhibitory
neurotransmitter in the CNS. The similarity of the spectrum
of physiological effects of Selank and classical benzodiazepines
(such as diazepam and phenazepam) suggests that there is a
similar basis of their mechanism of action; that is, the allosteric
modulation of GABAA receptors.
Previously, it was shown that in the presence of Selank the
amount of the specifically bound ligand, [3H] GABA, varied, and
preliminary intranasal administration of peptide also induced
changes in the number of specific binding sites of [3H] GABA
but did not affect the affinity of the receptors (V’Yunova et al.,
2014). Based on these data, the authors suggested that Selank can
lead to a rapid change in the state of the GABAergic system by
binding the peptide to GABA receptors and, thus, allosterically
modulating the activity of GABAA receptor.
In this study, we evaluated the contribution of the GABAergic
system to themolecular mechanism responsible for the anxiolytic
action of Selank. To test the hypothesis that Selank acts through
GABAA receptors, we investigated its effect on changes in the
mRNA levels of the genes encoding the major subunits of the
GABA receptors, transporters and ion channels involved in the
transport of GABA, and those of other proteins involved in
neurotransmission in rat brain 1 and 3 h after administration of
the peptide. To identify the effects associated with the activation
of GABAA receptors, we analyzed the changes in the expression
of the investigated genes in response to the action of the primary
ligand, GABA.
MATERIALS AND METHODS
Chemicals
Dry preparations of Selank (Nα-Thr-Lys-Pro-Arg-Pro-Gly-Pro-
Diacetate Salt) and GABA (γ-aminobutyric acid) were dissolved
to a concentration of 10mg/ml in deionized water.
Animal Model
The male Wistar rats with an average weight of 200 g were
used in the experiment. The animals were kept under the
standard conditions with free access to water and food, and a
12 h light/dark cycle. The animals (n = 30) were divided into
three groups: one control group (n1 = 10) and two experimental
groups: Selank group (n2 = 10) and GABA group (n3 = 10). A
single intranasal administration of the water solution of Selank
or GABA was performed on each animal from the experimental
groups (6µl at the concentration of 300µg to 1 kg of body
weight) and the equivalent volume of deionized water was
performed on each animal from the control group. Selank dose
of 300µg/kg was selected based on the data that this dose was the
most effective therapy dose exerting anxiolytic action (Seredenin
et al., 1998; Kozlovskaya et al., 2003). The first half of animals
from each group was decapitated 1 h after the administration of
the compounds, the second half—after 3 h. Immediately after the
decapitations, the rat frontal cortexes were dissected, placed into
sterile test tubes (free of RNase and DNase), and frozen in liquid
nitrogen with subsequent storage at−70◦C.
The animal experiments were carried out in accordance with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals (NIH publication No 80-23) and the
statement of the ethics committee of the Institute of Molecular
Genetics, Russian Academy of Sciences.
RNA Isolation and Reverse Transcription
Frontal cortex tissues obtained from each rat were pooled
according to the corresponding groups and time points, resulting
in six pools. Total RNA was extracted from each resulting pool
of tissues using the RNeasy R© Mini Kit (Qiagen, Germany)
according to the manufacturer’s protocol. First-strand cDNAs
were synthesized using the RT2 First Strand Kit (Qiagen,
Germany) according to the manufacturer’s protocol.
Real-Time Quantitative RT-PCR
The effect of Selank and GABA on the expression of genes
was studied with the help of the real-time PCR method
using a Custom RT2 Profiler™ PCR Array: CAPR11632
(Qiagen, Germany). Amplification was carried out on the device
StepOnePlus™ Real-Time qPCR System (Life Technologies,
USA) using the RT2 SYBR Green Mastermixes (Qiagen,
Germany). Thermal cycling was carried out as follows: (1) 95◦C
for 600 s, followed by (2) 40 cycles of 15 s at 95◦C and 60 s at 60◦C.
All reactions were repeated three times in each group for each
time point.
Statistical Analyses
The threshold reaction cycle (Ct) values obtained for the genes
under study were normalized to the Ct-values of the reference
genes. Statistical data analysis of the normalized Ct-values was
performed using the Relative Expression Software Tool 2009
(REST 2009) v.2.0.13, and Statistica 8.0. Genes with significant
changes (p ≤ 0.05) in the mRNA level by 1.5 times or more were
considered in the analysis to assess the changes in expression by
the action of the test compounds.
RESULTS
We studied the effects of Selank and GABA on changes in the
mRNA levels of 84 genes involved in neurotransmission in the
frontal cortex of rats 1 and 3 h after the intranasal administration
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of the compounds. The intranasal administration of Selank was
shown to be optimal for delivery of peptide molecules in the CNS
(Zolotarev et al., 2006; Ashmarin et al., 2008).
Preliminary analysis showed that, among the 84 studied genes,
seven genes (Csf2, Drd4, Htr3b, Il2, Mmp7, Mmp10, and Npffr2)
had a high threshold reaction cycle (Ct > 35), indicating a low
content of mRNA in the tissue. Therefore, these genes were
excluded from further analysis.
Of the remaining 77 genes, summarily 45 genes showed
changes in mRNA level 1 h after Selank or GABA administration
(Table 1). Twenty-five, or more than half of these 45 genes,
showed changes in mRNA level after administration of either
compound: Abat, Adcy7, Adora1, Bcl2l1, Cacna1a, Cacna1b,
Cx3cl1, Drd3, Drd5, Gabrb3, Gabre, Gabrq, HcRt, Hcrtr2, Htr3a,
Myc, Npffr1, Nsf, P2rx7, Prlhr, Slc32a1, Slc38a1, Slc6a1, Slc6a11,
and Slc8a3. The mRNA level of four genes (Drd1a, Drd2, Ptgs2,
and Slc6a13) changed only after Selank administration, and
that of 16 genes (Aldh5a1, Birc3, Birc5, Ccnd1, Egr1, Gabbr1,
Gabra1, Gabrb1, Gabrd, Gabrg3, Gad1, Glul, Htr1b, Jun, Junb, and
Slc6a12) changed only after GABA administration.
For 23 genes whose expression changed 1 h after
administration of either compound, a decrease in the mRNA
level was observed. The effect was especially pronounced for
three genes: Gabre (20 and 16.7 times for Selank and GABA,
respectively), Gabrq (20 and 20 times for Selank and GABA,
respectively), and Hcrt (25 and 50 times for Selank and GABA,
respectively). An increase in mRNA level was noted only for two
genes; the mRNA level of Drd3 increased 3.4 and 2 times after
Selank and GABA administration, respectively, and the mRNA
level of Gabrb3 increased 1.6 and 2.1 times after Selank and
GABA administration, respectively.
Of the 16 genes whose expression changed only after GABA
administration (1-h time point), 11 showed reduction in mRNA
expression, in particular Junb and Gabrd (2.8 and 2.7 times,
respectively). For the five genes Birc5, Gabra1, Gabrb1, Gabrg3,
and Glul, the increase in mRNA level was no greater than two
times compared with that of the control group. The genes whose
expression changed only after Selank administration (1-h time
point) were characterized by an increase inmRNA level, although
not more than 2 times; the mRNA levels of Drd2 and Ptgs2
increased 1.6 times, and those of Drd1a and Slc6a13 increased
by 2 times.
A different pattern was observed 3 h after Selank or GABA
administration. Expression changed in only 22 of the 77
genes selected for the analysis. The mRNA levels of 13
genes (Abat, Adcy7, Ccnd1, Drd5, Gabre, Gabrq, HcRt, Htr3a,
Prlhr, Slc32a1, Slc6a1, Slc6a11, and Slc8a3) changed only after
Selank administration. The mRNA levels of five genes (Cx3cl1,
Drd1a, Drd3, Gabra6, and Junb) changed only after GABA
administration. The mRNA levels of four genes (Adora2a,
Htr1b, Myc, and Npffr1) changed after administration of either
compound (Table 1). Level of mRNA increased for all genes
except for Drd3, whose mRNA level decreased 1.8 times after
GABA administration.
Similar to the pattern seen 1 h after Selank administration, at
3 h after administration of this compound, the most pronounced
changes in gene expression were observed for Hcrt, Gabre,
and Gabrq. At 3 h after Selank administration, the mRNA
levels of these genes increased 128.3, 16.1, and 13.3 times,
respectively. The mRNA level increased significantly 3 h after
GABA administration for only one gene, Gabra6, whose mRNA
level increased 7.6 times.
The aggregate analysis of all statistically significant data
showed that the total number of genes whose mRNA level
changed 1 h after administration of the test compounds (45
genes) was more than twice that of the genes whose expression
changed after 3 h (22 genes). Most of the genes (76%) showed
a decrease in mRNA level 1 h after administration of the test
compounds. By contrast, the mRNA level increased in nearly
almost all genes (95%) whose expression changed 3 h after
administration of the test compounds (Figure 1).
Although 1 h after GABA administration, mRNA level
changed in a substantial number of genes (53%, 41 of 77 genes),
3 h after GABA administration, the number of genes whose
expression changed was reduced to only 9 (12%). In contrast to
GABA, Selank affected the expression of fewer genes 1 h after
the administration (38%, 29 of 77 genes), but the reduction in
the number of genes whose expression changed 3 h after Selank
administration was smaller (22%, 17 of 77 genes).
Another interesting feature was revealed: at the 1-h time point;
56% of the genes exhibited changed expression regardless of the
test compound, whereas the change in expression was selective
for one compound for 44% of the genes. A different pattern
was seen at the 3 h-time point; only 18% of the genes exhibited
changed expression regardless of the test compound, whereas the
change in expression of 82% of the genes was selective for one
compound (Figure 2).
Correlation analysis was performed for those genes whose
mRNA level changed significantly after administration of the test
compounds. A positive correlation was observed between the
changes in gene expression within 1 h after administration of
Selank or GABA (r = 0.86; p ≤ 0.05). By contrast, a negative
correlation was observed between the changes in gene expression
at the 3-h time-point after the administration of Selank or GABA
(r =−0.39; p ≤ 0.05).
DISCUSSION
Numerous clinical studies have shown that Selank has strong
antianxiety and neuroprotective effects in the treatment of
generalized anxiety disorders. The clinical effects of Selank are
similar to those of the classical antianxiety medications such
as benzodiazepines, which are allosteric modulators of GABAA
receptors and increase the inhibitory action of GABA (Seredenin
et al., 1990, 1998). This suggests that the molecular mechanism of
action of Selank arises from its ability to affect GABA receptors.
To test this hypothesis, we assessed the changes in the mRNA
levels of 84 genes encoding proteins related to the functioning of
the GABAergic system, as well as those of proteins involved in
neurotransmission in the frontal cortex of rats 1 and 3 h after the
administration of Selank or GABA.
Our results suggest that Selank is able to directly influence
the expression of genes involved in neurotransmission in nerve
cells, and similar changes in the expression of these genes are also
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TABLE 1 | The relative mRNA levels of genes involved in neurotransmission in rat frontal cortex one and three hours after the administration of Selank or
GABA (the table lists only the genes which showed a statistically significant change in mRNA levels).
Gene
symbol
Official full name 1 h 3 h
Selank GABA Selank GABA
Fold
change
p-value Fold
change
p-value Fold
change
p-value Fold
change
p-value
S
u
b
u
n
its
o
f
th
e
G
A
B
A
re
c
e
p
to
rs
Gabbr1 Gamma-aminobutyric acid (GABA) B
receptor 1
0.74 0.0111 0.57* 0.0002 1.36 0.0013 1.19 0.0247
Gabra1 Gamma-aminobutyric acid (GABA) A
receptor, alpha 1
1.33 0.0531 1.94* 0.0002 0.73 0.0015 0.93 0.1772
Gabra6 Gamma-aminobutyric acid (GABA) A
receptor, alpha 6
1.25 0.4384 1.55 0.0968 0.83 0.1942 7.56* 0.0004
Gabrb1 Gamma-aminobutyric acid (GABA) A
receptor, beta 1
1.09 0.1980 1.57* 0.0005 0.94 0.0970 0.82 0.0096
Gabrb3 Gamma-aminobutyric acid (GABA) A
receptor, beta 3
1.58* 0.0006 2.07* 0.0009 0.86 0.0211 0.95 0.3392
Gabrd Gamma-aminobutyric acid (GABA) A
receptor, delta
0.81 0.0366 0.37* 0.0015 0.88 0.0807 1.20 0.0479
Gabre Gamma-aminobutyric acid (GABA) A
receptor, epsilon
0.05* 0.000009 0.06* 0.000008 16.10* 0.0002 1.06 0.7443
Gabrg3 Gamma-aminobutyric acid (GABA) A
receptor, gamma 3
1.29 0.0147 1.95* 0.0009 0.98 0.5120 1.00 0.9307
Gabrq Gamma-aminobutyric acid (GABA)
receptor, theta
0.05* 0.000019 0.05* 0.00002 13.30* 0.00001 1.21 0.2129
D
o
p
a
m
in
e
re
c
e
p
to
rs
Drd1a Dopamine receptor D1A 1.98* 0.0037 0.89 0.0762 1.36 0.0003 1.76* 0.0011
Drd2 Dopamine receptor D2 1.60* 0.0002 1.30 0.0001 1.11 0.0040 1.46 0.0001
Drd3 Dopamine receptor D3 3.36* 0.0047 1.96* 0.0061 0.83 0.1832 0.57* 0.0144
Drd5 Dopamine receptor D5 0.40* 0.0065 0.25* 0.0015 1.59* 0.0293 0.93 0.6347
S
e
ro
to
n
in
re
c
e
p
to
rs
Htr1b 5-hydroxytryptamine (serotonin)
receptor 1B
0.83 0.1542 0.58* 0.0004 1.59* 0.0090 1.57* 0.0145
Htr3a 5-hydroxytryptamine (serotonin)
receptor 3a
0.52* 0.0019 0.38* 0.0011 1.66* 0.0036 1.13 0.1647
Io
n
c
h
a
n
n
e
ls
Cacna1a Calcium channel, voltage-dependent,
P/Q type, alpha 1A subunit
0.58* 0.0005 0.43* 0.000003 1.09 0.2884 1.06 0.4953
Cacna1b Calcium channel, voltage-dependent, N
type, alpha 1B subunit
0.64* 0.0004 0.33* 0.0086 1.35 0.0068 1.08 0.0782
P2rx7 Purinergic receptor P2X, ligand-gated
ion channel, 7
0.53* 0.0004 0.22* 0.000012 1.40 0.0207 1.27 0.039947
Tr
a
n
sp
o
rt
e
rs
Slc32a1 Solute carrier family 32 (GABA vesicular
transporter), member 1
0.50* 0.0025 0.26* 0.0001 1.82* 0.0011 1.32 0.0299
Slc38a1 Solute carrier family 38, member 1 0.65* 0.0010 0.57* 0.0001 1.22 0.0177 1.07 0.3890
Slc6a1 Solute carrier family 6 (neurotransmitter
transporter, GABA), member 1
0.41* 0.0010 0.20* 0.0001 1.53* 0.0015 1.29 0.0696
Slc6a11 Solute carrier family 6 (neurotransmitter
transporter, GABA), member 11
0.29* 0.000032 0.18* 0.000008 2.29* 0.000018 1.05 0.5046
Slc6a12 Solute carrier family 6 (neurotransmitter
transporter, betaine/GABA), member 12
1.31 0.0615 0.39* 0.0024 0.99 0.9666 0.80 0.2473
Slc6a13 Solute carrier family 6 (neurotransmitter
transporter, GABA), member 13
1.97* 0.0002 0.69 0.0041 1.04 0.1453 0.88 0.0041
Slc8a3 Solute carrier family 8 (sodium/calcium
exchanger), member 3
0.55* 0.0036 0.43* 0.0007 1.67* 0.0006 1.44 0.0055
(Continued)
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TABLE 1 | Continued
Gene
symbol
Official full name 1 h 3 h
Selank GABA Selank GABA
Fold
change
p-value Fold
change
p-value Fold
change
p-value Fold
change
p-value
O
th
e
r
g
e
n
e
s
in
vo
lv
e
d
in
n
e
u
ro
tr
a
n
sm
is
si
o
n
Abat 4-aminobutyrate aminotransferase 0.40* 0.0001 0.27* 0.0001 1.65* 0.0019 1.35 0.0493
Adcy7 Adenylate cyclase 7 0.25* 0.0013 0.16* 0.0009 3.21* 0.0004 1.23 0.0073
Adora1 Adenosine A1 receptor 0.57* 0.0011 0.40* 0.0001 1.36 0.0077 1.47 0.0046
Adora2a Adenosine A2a receptor 1.44 0.0026 0.73 0.0149 1.51* 0.0002 2.06* 0.000014
Aldh5a1 Aldehyde dehydrogenase 5 family,
member A1
0.68 0.0003 0.56* 0.0001 1.22 0.0080 0.99 0.9439
Bcl2l1 Bcl2-like 1 0.63* 0.0005 0.50* 0.000001 1.32 0.0010 1.11 0.0627
Birc3 Baculoviral IAP repeat-containing 3 1.27 0.0716 0.40* 0.0253 1.33 0.1432 0.93 0.8034
Birc5 Baculoviral IAP repeat-containing 5 1.25 0.0653 1.93* 0.0008 0.73 0.000047 0.80 0.0019
Ccnd1 Cyclin D1 0.70 0.0092 0.43* 0.0006 1.72* 0.0001 1.34 0.0235
Cx3cl1 Chemokine (C-X3-C motif) ligand 1 0.56* 0.0073 0.24* 0.0003 1.42 0.0173 1.50* 0.0200
Egr1 Early growth response 1 1.17 0.0230 0.66* 0.0103 1.10 0.0145 1.21 0.0053
Gad1 Glutamate decarboxylase 1 0.78 0.0021 0.53* 0.0001 1.21 0.0072 1.15 0.0390
Glul Glutamate-ammonia ligase (glutamine
synthetase)
1.48 0.0014 1.72* 0.0008 0.82 0.0148 0.95 0.4578
HcRt Hypocretin 0.04* 0.000001 0.02* 0.000001 128.29* 0.000001 1.11 0.4062
Hcrtr2 Hypocretin (orexin) receptor 2 0.45* 0.0018 0.66* 0.0034 1.44 0.0015 1.00 0.9990
Jun Jun oncogene 0.72 0.0010 0.60* 0.0105 0.94 0.1465 0.99 0.5810
Junb Jun B proto-oncogene 0.74 0.0191 0.36* 0.000031 1.45 0.0022 1.51* 0.0091
Myc Myelocytomatosis oncogene 0.59* 0.0005 0.35* 0.0003 1.75* 0.0288 1.83* 0.0015
Npffr1 Neuropeptide FF receptor 1 0.21* 0.0031 0.16* 0.0027 3.09* 0.0004 1.66* 0.0200
Nsf N-ethylmaleimide-sensitive factor 0.61* 0.0013 0.53* 0.0003 1.30 0.0091 1.26 0.0378
Prlhr Prolactin releasing hormone receptor 0.38* 0.0233 0.13* 0.0083 2.51* 0.000022 1.04 0.4964
Ptgs2 Prostaglandin-endoperoxide synthase 2 1.58* 0.0012 1.34 0.0097 0.93 0.0262 1.05 0.1204
The number of genes whose mRNA level changed 29 41 17 9
45 22
The mRNA levels of genes in the control group are taken as the baseline. * and the bold values denote changes in the expression by 1.5 times or more, with a significance level p ≤
0.05.
observed when GABA is administered. This is supported by the
strong positive correlation between the changes in the expression
of 45 genes 1 h after the Selank or GABA administration.
However, the match between the expression profiles of these
genes is not perfect. Thus, in addition to the 25 genes affected
by either of the test compounds, GABA but not Selank affected
the mRNA level of another 16 genes 1 h after administration.
This difference in the number of genes whose expression changed
suggests that Selank acts not directly through the center of the
specific binding of GABA, but rather allosterically by altering
the affinity of the GABA receptor for GABA. Previously, it
was shown that Selank is able to affect the specific binding of
GABA to its own receptors, which may be caused by modulating
properties of regulatory peptide, which apparently change the
affinity of endogenous ligands under the influence of Selank on
the receptor (V’Yunova et al., 2014). We can assume that the
observed similarity of expression profiles of our study genes
after administration of Selank and GABA partly confirms the
hypothesis about the possible effect of the peptide through the
regulation of the activity of GABAA receptors.
We note that, compared with the 1-h time point, there was a
sharp decrease at 3 h in the number of genes whose expression
changed after exposure to GABA. The large number of genes
whose mRNA level changed 1 h after GABA administration
suggests that rapid effects were caused by binding of GABA
to GABAA receptors. This binding leads to the opening of ion
channels in the nerve cell membrane of and the subsequent
entry of chloride ions through the channels (MacDonald and
Olsen, 1994). The absence of significant changes 3 h after GABA
administration may be associated with a gradual decrease in
the activity of the major elements of the GABAergic system.
In contrast to GABA, a significant reduction in the number of
genes whose expression changed 3 h after Selank administration
was not observed. This suggests that Selank activates alternative
processes, which cause delayed changes in the expression of
certain genes that do not relate directly to the operation of
the GABAergic system but at the same time contribute to the
activation of certain genes involved in its operation.
Interestingly, the mRNA levels of four genes (Drd1a, Drd2,
Ptgs2, and Slc6a13) altered only under the influence of Selank
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FIGURE 1 | The ratio of the number of genes with altered mRNA levels.
The proportions shown were normalised to the total number of genes with
changed mRNA expression.
FIGURE 2 | The ratio of the number of genes that change levels of
mRNA in the selective and nonselective action of the compounds. The
proportions shown are relative to the total number of genes that change the
level of mRNA in the appropriate time period.
at the 1-h time point. Intriguing results were obtained in
relation to Slc6a13, which encodes the low-affinity transporter
of the GABA GAT-2. GAT-2 plays a key role in peripheral
mechanisms involved in the work of GABAergic system and
is also responsible for the redistribution and metabolism of
drugs, which can affect the operation of the GABAergic system
(Schlessinger et al., 2012). Thus, activation of the carrier only
after exposure to Selank suggests the presence of an alternative
path of action of the peptide on the distribution of peripheral
GABA. Drd2 and Drd1a encode dopamine receptors, which are
associated with G-protein and are involved in the regulation of
adenylate cyclase activity, thereby mediating intracellular signal
transduction (Beaulieu and Gainetdinov, 2011). The activation
of Drd5 expression at the 3-h time point was observed only
for Selank. Drd5 encodes the dopamine receptor, which plays
a key role in the formation of memory and learning processes
by ensuring long-term potentiation (Beaulieu and Gainetdinov,
2011). Activation of this gene by Selank at early and later times
suggests an ability of the peptide to influence processes involved
in synaptic plasticity and thereby render nootropic action. It
has been shown previously that Selank modulates dopamine
and serotonin receptors, which play a role in the stimulation of
mental activity and in the pathogenesis of anxiety (Meshavkin
et al., 2006).
Of particular interest is the significant change in the mRNA
level of Hcrt 3 h after Selank administration. This gene encodes
a precursor of orexins and is involved in the regulation of
the balance between sleep and wakefulness (Ohno and Sakurai,
2008). Kolomin et al. have shown that the mRNA level of theHcrt
increases after a single administration of Selank (Kolomin et al.,
2013). The presence of this significant effect of Selank suggests
that the peptide has an active effect on the balance between
sleep and wakefulness, and that the change in the expression of
Hcrt may be in the foundation of the normalizing effect Selank
has on the balance of sleep patterns in patients with general
anxiety disorders. The observed changes may also explain the
lack of hypnosedative action of Selank, which is common for
classical benzodiazepines, because of the shift in the balance
toward wakefulness.
Thus, our obtained data indicate that, like other peptide drugs,
Selank is characterized by its complex effects on nerve cells. One
of its possible molecular mechanisms is associated with allosteric
modulation of the operation of the GABAergic system. At the
same time, Selank may act through other systems such as the
dopamine and serotonergic systems. Further research is needed
to identify all aspects of the mechanisms of action of Selank and
the effects of this peptide on various neurotransmitter systems in
different models.
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